David Dean Stenehjem

机构：University of Minnesota, University of Utah, University of Minnesota, Duluth · ORCID：0000-0002-1831-285X

发表论文 245 篇 · 总被引 2893 次 · h-index 23

代表论文

• High rifaximin out-of-pocket costs are associated with decreased treatment retention among patients with hepatic encephalopathy (2023 · Hepatology Communications · 被引 10)
• A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations. (2024 · Journal of Clinical Oncology · 被引 7)
• Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers (2024 · Journal of Managed Care & Specialty Pharmacy · 被引 6)
• Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty (2023 · Journal of Geriatric Oncology · 被引 6)
• Abstract CT196: First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors (2024 · Cancer Research · 被引 3)
• CO95 Matching-Adjusted Indirect Comparison (MAIC) in Previously Treated KRAS G12C-Mutated Advanced/Metastatic Non-Small Cell Lung Cancer (a/mNSCLC): Adagrasib Versus Sotorasib (2023 · Value in Health · 被引 3)